MSB 2.03% $1.45 mesoblast limited

Why a trial?, page-45

  1. 693 Posts.
    lightbulb Created with Sketch. 266

    It is true that most companies resist publishing their CRL's (probably for good reason!), and that is not quite what I'm suggesting.

    I think shareholders ought to be given a summary of the key points in the CRL. We do not have that - indeed we know almost nothing of the CRL, for example we don't even know whether or not the CMC package is OK. Without any information, people will naturally think the worst - maybe the CRL is not as bad as we all think!!

    At the moment, the market is uninformed.
 
watchlist Created with Sketch. Add MSB (ASX) to my watchlist
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.